ModiQuest Research BV has announced that it has entered into a collaboration with Cellectis aimed at the generation of novel monoclonal antibodies against Cellectis’ target(s).
During the collaboration, ModiQuest may make use of its proprietary electrofusion technology, ModiFuse™. Financial details of the collaboration were not disclosed.
“We are pleased that Cellectis has selected ModiQuest Research as a development partner for its activities,” said Dr. Jos Raats, Managing Director of ModiQuest Research. “This collaboration once more demonstrates the value of our broad and unique antibody generation platform and we are delighted to work together with Cellectis in the emerging field of cancer immunotherapy.”